Tiger Hunt, 1838–1840

Zoologist John Gould undertook a financially risky expedition to document the birds of Australia—and found some unique mammals in a perilous situation.

Aug 1, 2014
Jef Akst

THE WONDER DOWN UNDER: Almost immediately after landing in Tasmania (better known at the time as Van Diemen’s Land) on September 18, 1838, Gould and traveling companion John Gilbert set out exploring. One inhabitant they documented was the Tasmanian tiger, which often attacked the island’s domestic animals. “The destruction [by this species] has, as a matter of course, called forth the enmity of the settler, and hence in all cultivated districts the animal is nearly extirpated,” Gould wrote. The plate above was completed by zoological illustrator Henry Constantine Richter, though many of Gould’s works were principally illustrated by his wife, natural history artist Elizabeth Coxen.© RICHTER, HENRY CONSTANTINE (1821-1902)/PRIVATE COLLECTION/BRIDGEMAN IMAGESIn May 1838, John Gould, a British zoologist and staff taxidermist for the Zoological Society of London, set sail for Australia. His wife’s brothers had emigrated to the island continent nearly a decade earlier and had been sending Gould specimens of Australian birds, the vast majority of which were new to science. Having already published popular volumes on the birds of the Himalayas and of Europe, he immediately saw the value of a collection about Australian birdlife, but realized that working from dead specimens wasn’t going to cut it; he needed to see them in their natural habitat.

Along with his wife, his eldest son, a young nephew, zoological collector John Gilbert, and a couple of servants, Gould set off for Australia. Unlike many of his contemporaries, who were born into wealthy families and could undertake such expeditions without much concern for the financial consequences, “[Gould’s] Australia trip was an incredibly risky entrepreneurial enterprise,” says Jonathan Smith, a University of Michigan–Dearborn English professor who studies 19th-century literature and science. “It’s very clear from his correspondence that if he isn’t successful with this publication, there aren’t going to be any more John Gould bird folios.”

So once the family arrived that September, in addition to observing, collecting, and describing the fauna he found, Gould spent a good deal of time trying to acquire folio subscribers. Luckily, he had a good sales pitch. “Everything about Australian animal life was unusual,” compared to the organisms that had so far been documented by naturalists, says Smith. “[Gould] saw that both from a scientific and entrepreneurial standpoint.”

It wasn’t just the birds that caught his attention; he found the mammals of Australia and the surrounding islands equally fascinating. One animal described in detail in the resulting Mammals of Australia, published in three volumes between 1845 and 1863, is the now-extinct Tasmanian tiger (Thylacinus cynocephalus). In his description of the striped marsupial, Gould predicted its demise: “When the comparatively small island of Tasmania becomes more densely populated, and its primitive forests are intersected with roads from the eastern to the western coast, the numbers of this singular animal will speedily diminish, extermination will have its full sway, and it will then, like the Wolf in England and Scotland, be recorded as an animal of the past: although this will be a source of much regret, neither the shepherd nor the farmer can be blamed for wishing to rid the island of so troublesome a creature.”

The animal was hunted exhaustively to protect local sheep herds, and nearly 100 years after Gould wrote these words, the last known Tasmanian tiger died. “They were vilified and killed off,” says Penn State genomicist Webb Miller.

In the end, Gould’s Australian adventure proved successful both financially and scientifically, says Smith, and “it enabled him to move on to even bigger and better things,” such as a spectacularly popular folio on hummingbirds. In total, he published 41 volumes with some 3,000 plates during his career. “Gould was a working-class kid, and he rises to become this fabulously successful entrepreneur [and] one of the top ornithologists in Victorian Britain,” says Smith. “It’s an interesting rags-to-riches story.” 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.